Sutro Biopharma, Inc. (S09.F)

3.1200 -0.1600 (-4.88%) At close: 09:15AM CEST

Sutro Biopharma, Inc.

111 Oyster Point Boulevard
South San Francisco, CA 94080
United States
650 881 6500
https://www.sutrobio.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 297

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. William J. Newell J.D.	CEO & Director	1.07M	N/A	1958
Ms. Jane Chung R.Ph.	Chief Commercial Officer	934.64k	N/A	1971
Dr. James R. Swartz Ph.D., Sc.D.	Founder	N/A	N/A	N/A
Mr. Edward C. Albini	CFO & Sec.	N/A	N/A	1958
Dr. Venkatesh Srinivasan Ph.d.	Chief Technical Operations Officer	N/A	N/A	N/A
Mr. David Pauling J.D., M.A.	Gen. Counsel	N/A	N/A	N/A
Ms. Linda A. Fitzpatrick	Chief People & Communications Officer	N/A	N/A	1957
Dr. Nicki Vasquez Ph.D.	Chief Portfolio Strategy & Alliance Officer	N/A	N/A	1963
Ms. Brunilda Shtylla M.B.A., M.S.	Chief Bus. Officer	N/A	N/A	1974
Dr. Anne Elizabeth Borgman-Hagey M.D.	Chief Medical Officer	N/A	N/A	1968

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Sutro Biopharma, Inc. operates as a clinical-stage oncology company. It develops site-specific and novel-format antibody drug conjugates (ADC) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. The company's product candidates include STRO-001, an ADC directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. Its pre-clinical product candidate STRO-003, a ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology; EMD Serono to develop ADCs for multiple cancer targets; and Astellas Pharma Inc. to develop ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.

Corporate Governance

Sutro Biopharma, Inc.’s ISS Governance QualityScore as of September 1, 2023 is 7. The pillar scores are Audit: 3; Board: 6; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.